Amylin's long-delayed diabetes drug gets FDA nod
Saturday, January 28, 2012 - 06:23
in Health & Medicine
Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine, Byetta.